SIMCERE PHARMA (02096) Plans to Spin Off SIMCERE RENMING's H Shares for Separate Listing on SEHK Main Board

Stock News01-09

SIMCERE PHARMA (02096) announced that the company proposes to spin off its subsidiary SIMCERE RENMING's H shares for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited (SEHK). The independent listing of SIMCERE RENMING's H shares on the SEHK Main Board constitutes a spin-off of SIMCERE RENMING by the company under Practice Note 15. The SEHK has confirmed that the company may proceed with the proposed spin-off.

On January 9, 2026, SIMCERE RENMING submitted the Application Form (Form A1) to the SEHK to apply for the listing of, and permission to deal in, its H shares on the Main Board. Under the plan, SIMCERE RENMING will conduct a new share offering for the proposed listing.

Subject to certain conditions, qualified shareholders will be provided with guaranteed quotas for SIMCERE RENMING H shares through preferential applications under the global offering. Upon completion of the proposed spin-off and the proposed listing, the company expects to retain an interest exceeding 50% in SIMCERE RENMING, which will consequently remain a subsidiary of the company.

SIMCERE RENMING is a biopharmaceutical enterprise at the forefront of global drug innovation, focusing on the research, development, and commercialization of innovative oncology drugs (excluding drugs related to cell therapies and genetic diagnosis and treatment technologies).

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1125028503?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-09 22:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1125028503","market":"us","top_or_hot":-1,"title":"SIMCERE PHARMA (02096) Plans to Spin Off SIMCERE RENMING's H Shares for Separate Listing on SEHK Main Board","media":"Stock News","content":"<p>SIMCERE PHARMA (02096) announced that the company proposes to spin off its subsidiary SIMCERE RENMING's H shares for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited (SEHK). The independent listing of SIMCERE RENMING's H shares on the SEHK Main Board constitutes a spin-off of SIMCERE RENMING by the company under Practice Note 15. The SEHK has confirmed that the company may proceed with the proposed spin-off.</p>\n<p>On January 9, 2026, SIMCERE RENMING submitted the Application Form (Form A1) to the SEHK to apply for the listing of, and permission to deal in, its H shares on the Main Board. Under the plan, SIMCERE RENMING will conduct a new share offering for the proposed listing.</p>\n<p>Subject to certain conditions, qualified shareholders will be provided with guaranteed quotas for SIMCERE RENMING H shares through preferential applications under the global offering. Upon completion of the proposed spin-off and the proposed listing, the company expects to retain an interest exceeding 50% in SIMCERE RENMING, which will consequently remain a subsidiary of the company.</p>\n<p>SIMCERE RENMING is a biopharmaceutical enterprise at the forefront of global drug innovation, focusing on the research, development, and commercialization of innovative oncology drugs (excluding drugs related to cell therapies and genetic diagnosis and treatment technologies).</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SIMCERE PHARMA (02096) Plans to Spin Off SIMCERE RENMING's H Shares for Separate Listing on SEHK Main Board</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSIMCERE PHARMA (02096) Plans to Spin Off SIMCERE RENMING's H Shares for Separate Listing on SEHK Main Board\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-09 22:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SIMCERE PHARMA (02096) announced that the company proposes to spin off its subsidiary SIMCERE RENMING's H shares for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited (SEHK). The independent listing of SIMCERE RENMING's H shares on the SEHK Main Board constitutes a spin-off of SIMCERE RENMING by the company under Practice Note 15. The SEHK has confirmed that the company may proceed with the proposed spin-off.</p>\n<p>On January 9, 2026, SIMCERE RENMING submitted the Application Form (Form A1) to the SEHK to apply for the listing of, and permission to deal in, its H shares on the Main Board. Under the plan, SIMCERE RENMING will conduct a new share offering for the proposed listing.</p>\n<p>Subject to certain conditions, qualified shareholders will be provided with guaranteed quotas for SIMCERE RENMING H shares through preferential applications under the global offering. Upon completion of the proposed spin-off and the proposed listing, the company expects to retain an interest exceeding 50% in SIMCERE RENMING, which will consequently remain a subsidiary of the company.</p>\n<p>SIMCERE RENMING is a biopharmaceutical enterprise at the forefront of global drug innovation, focusing on the research, development, and commercialization of innovative oncology drugs (excluding drugs related to cell therapies and genetic diagnosis and treatment technologies).</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02096","symbol_name":"先声药业","start_time":0,"source_url":"","article_id":"1125028503","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1125028503","pubTimestamp":1767968424,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"SIMCERE PHARMA (02096) announced that the company proposes to spin off its subsidiary SIMCERE RENMING's H shares for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02096":"先声药业","BK1583":"高瓴概念","BK1191":"制药"},"translate_title":"先声药业(02096)拟分拆先声仁明H股于联交所主板单独上市","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02096":1},"content_text":"SIMCERE PHARMA (02096) announced that the company proposes to spin off its subsidiary SIMCERE RENMING's H shares for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited (SEHK). The independent listing of SIMCERE RENMING's H shares on the SEHK Main Board constitutes a spin-off of SIMCERE RENMING by the company under Practice Note 15. The SEHK has confirmed that the company may proceed with the proposed spin-off.\nOn January 9, 2026, SIMCERE RENMING submitted the Application Form (Form A1) to the SEHK to apply for the listing of, and permission to deal in, its H shares on the Main Board. Under the plan, SIMCERE RENMING will conduct a new share offering for the proposed listing.\nSubject to certain conditions, qualified shareholders will be provided with guaranteed quotas for SIMCERE RENMING H shares through preferential applications under the global offering. Upon completion of the proposed spin-off and the proposed listing, the company expects to retain an interest exceeding 50% in SIMCERE RENMING, which will consequently remain a subsidiary of the company.\nSIMCERE RENMING is a biopharmaceutical enterprise at the forefront of global drug innovation, focusing on the research, development, and commercialization of innovative oncology drugs (excluding drugs related to cell therapies and genetic diagnosis and treatment technologies).","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1125028503","isCrawlerRequest":true}